A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies
Clinical trial NCT05453903 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05453903
- Sponsor
- Janssen Research & Development, LLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2022-10-04
- Primary completion
- 2026-10-30
- Enrollment
- 196
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.